People · Operator
Named in public records as an officer, director or promoter · active 2010–2021 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cyteir Therapeutics, Inc. | — | Biotechnology | Series C | $111.9M | $2.6B | 2019 |
| Agile Therapeutics Inc | — | Pharmaceuticals | Series B | $89.6M | $266.5M | 2010 |
| StrideBio, Inc. | — | Biotechnology | Series C | $57.7M | $1.5B | 2021 |
| Obsidian Therapeutics, Inc. | — | Biotechnology | Series B | $32.4M | $1.3B | 2017 |
Karen Hong at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Karen Hong on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Barrett | 1 | 18 |
| Richard Smith | 1 | 11 |
| Michael Martin | 1 | 11 |
| Clay Thorp | 1 | 10 |
| David Neafus | 1 | 7 |
| Michael Gilman | 1 | 6 |
| Robert Hughes | 1 | 6 |
| Jean George | 1 | 6 |
| JOSEPH S. ZAKRZEWSKI | 1 | 6 |
| Andrew Schiff | 1 | 5 |
| JASON GARDNER | 1 | 5 |
| Shaan Gandhi | 1 | 4 |
| Kevin Mills | 1 | 4 |
| Sapan Shah | 1 | 4 |
| Erica Whittaker | 1 | 3 |
| Abhijeet Lele | 1 | 3 |
| Janwillem Naesens | 1 | 3 |
| Russell W. Ayres | 1 | 2 |
| Paul J. Schmitt | 1 | 2 |
| Al M. Altomari | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.